Understaffing 'strains ability' of Indian regulator, parliamentary report says
This article was originally published in Scrip
In another indictment of India's drug regulatory body, a report by a parliamentary standing committee on health and family welfare has said that the Central Drugs Standard Control Organisation (CDSCO) is "substantially" understaffed and functioning with less that 50% of the required permanent manpower strength.
You may also be interested in...
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.